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Background: Most people prefer to receive end-of-life care in familiar surroundings rather than in hospital. This
study examines variation in place of death for people dying from Parkinson’s disease (PD) across 11 European and
non-European countries.
Methods: Using death certificate data of 2008 for Belgium, France, Italy, Hungary, Czech Republic, New Zealand,
USA, Canada, Mexico, South Korea and Spain for all deaths with PD as an underlying cause (ICD-10 code: G20)
cross-national differences in place of death were examined. Associations between place of death and patient
socio-demographic and regional characteristics were evaluated using multivariable binary logistic regression
analyses.
Results: The proportion of deaths in hospital ranged from 17% in the USA to 75% in South Korea. Hospital was
the most prevalent place of death in France (40%), Hungary (60%) and South Korea; nursing home in New
Zealand (71%), Belgium (52%), USA (50%), Canada (48%) and Czech Republic (44%); home in Mexico (73%), Italy
(51%) and Spain (46%). The chances of dying in hospital were consistently higher for men (Belgium, France,
Italy, USA, Canada), those younger than 80 years (Belgium, France, Italy, USA, Mexico), and those living in areas
with a higher provision of hospital beds (Italy, USA).
Conclusions: In several countries a substantial proportion of deaths from PD occurs in hospitals, although this
may not be the most optimal place of terminal care and death. The wide variation between countries in the
proportion of deaths from PD occurring in hospital indicates a potential for many countries to reduce these
proportions.
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With population ageing and possibly other etiological
factors the number of people living with Parkinson’s
disease is expected to grow substantially in the coming
decades [1].
The provision of optimal end-of-life care for people
living with Parkinson’s disease is challenging because the
disease trajectory is longer and less predictable than
other progressive illnesses such as cancer [2]. In* Correspondence: Katrien.Moens@kcl.ac.uk
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unless otherwise stated.advanced stages of Parkinson’s disease, sufferers are also
more likely to develop several co-morbidities and com-
plications, such as thrombosis, infections of the lung
and urinary tract, and dementia [3,4]. Their progressive
decline in function and increasing dependency on others
for care often results in people with Parkinson’s disease
needing institutional long-term care (LTC) [4].
One of the objectives of palliative care is enabling
patients to die where they prefer [5] and ‘place of death’
has been proposed as a quality indicator of palliative
care [6]. Most people would prefer to die in familiar
surroundings, such as at home or in the nursing home
where they live [7]. Although hospitals may be a com-
mon place of death, the evidence shows that hospitalsThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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in less favourable outcomes for patients and their
relatives [8].
Until now, comparative international place of death
research focused on people with Parkinson’s disease has
not been reported.
We aim to answer 1) what is the place of death for
people dying from Parkinson’s disease across European
and non-European countries, and 2) to what extent are
demographic, social, residential and health care system
factors associated with dying in a hospital in these
countries?
Methods
Study design
Procedures
This study is part of the International Place of Death
(IPoD) study, collecting death certificate data for the full
population of deaths for a period of one year in several
countries [9].
An open call tendering for partners was launched by
the principal investigators of the study. Candidate part-
ners were required to negotiate with national health or
other authorities to collect all individual death certificate
data of 2008 or the nearest available year, including place
of death and factors indicated in the literature as rele-
vant predictors of the place of death [10] for inclusion in
an international database. The year 2008 was chosen as
a reference year because an exploration of all candidate
partners learned that, at the time of the data collection
(2011–2013), this was the most recent available year in
all targeted countries together. Fourteen of 27 candidate
countries were able to obtain all necessary permissions
to use the national death certificate data and have these
integrated into an international database.
Population
For this study we used the death certificate data of
eleven countries: Belgium, France, Italy, Spain (only
Andalusia region), Hungary, Czech Republic, New
Zealand, USA, Canada (excluding Quebec province),
Mexico and South Korea (Nall deaths = 4,925,862). These
eleven countries provided data with three or four digit
International Classification of Diseases (ICD)-10 codes
[11] which allowed us to select deaths with Parkinson’s
disease as underlying cause of death (ICD-10 code for
Parkinson’s disease: G20). The three countries that were
not included provided the underlying cause of death in
aggregated categories due to data protection measures.
Some death certificates contain socio demographic in-
formation of the deceased, information often supplied by
a civil servant of the civil registrar of the municipality of
death, for other countries this information is not avail-
able through death certificates. However, linkage withother databases (e.g. census data) allowed inclusion of a
minimum number of socio demographic and environ-
mental related variables in most countries.
Measurements
The dependent variable for our study is place of death
i.e. home, hospital, LTC-setting, and hospice (only avail-
able as a separate category on the death certificate data
in New Zealand and the USA), other institution (e.g. in-
stitutions for people living with mental disabilities) and
other (e.g. public road). The death certificated data of
the USA captured free standing hospice inpatient units
and not the hospital based palliative care units. To de-
scribe the place of death across countries we combined
‘other institution’ and ‘other’ into one category (‘other’).
To examine which factors are associated with hospital
death within each country we dichotomized hospital ver-
sus all other places of death.
As independent variables we used four categories of
factors [10]: 1) demographic and social factors: sex, age
(<65, 65–79 and 80+) and educational attainment (no
formal or elementary, lower secondary, higher secondary,
and higher); 2) social support: marital status (unmarried,
married, widowed, and divorced/separated); 3) residential
factors: the degree of urbanization of the place of residence
(strong/very strong, average, weak/rural); and 4) health
care system factors: mean number of provided hospital
beds within the health care region per 1000 inhabitants
and mean number of beds within the health care region in
LTC-settings per 1000 inhabitants 65+ years. Educational
attainment was not available for France, New Zealand and
Canada. Marital status was not available for New Zealand.
Urbanization level was not available for the Czech
Republic, New Zealand, USA and Mexico. In Canada
information concerning the urbanization level was only
available for two categories: urban or rural.
For Belgium, France, Italy, Spain, New Zealand, USA,
Canada and Mexico the data on mean number of long
term care beds provided per 1000 inhabitants aged 65+
and mean number of hospital beds provided per 1000
inhabitants were supplied per health care or administra-
tive region. For Hungary, Czech Republic and South
Korea these were provided only for the country as a
whole as data protection regulations precluded having
data on region of residence.
Data analysis
To describe the bivariate associations between each
independent variable and place of death (hospital death
versus all other places of death) we used contingency
tables and X2 tests (significance level: p ≤ 0.05).
For each country separately, we used a multivariable
binary logistic regression model to estimate the factors
associated with dying in a hospital. A forward stepwise
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method was used to construct the best-fitting but still
parsimonious model. In this model some of the categor-
ies of the independent variables were combined into
two-category variables: age (−80 years vs. 80+), educa-
tional attainment (no formal or elementary and lower
secondary vs. higher secondary and higher), marital
status (unmarried, widowed and divorced/separated vs.
married), and urbanization level (average/weak/rural vs.
very strong/strong).
We used SPSS version 18.0 for all statistical
computations.
Ethics
The use of anonymised death certificate data did not
require research ethics approval. However, the necessary
permissions from the data protection agencies were
obtained in all countries providing data for the study.
Results
Study population
The proportion of people dying from Parkinson’s disease
ranged from 0.1% in Czech Republic to 0.8% in Belgium,
France, USA and Canada (Table 1). At least half were
male, except in South Korea where 56.3% were female.
The majority of the people dying from Parkinson’s
disease were 80+ years old across all countries, except
for South Korea and Hungary where the majority was
younger than 80. In all countries, more than 45% were
married, while between 36% (in Mexico) and 46% (in
South Korea) were widowed.
Place of death
Only in two countries, home was the predominant site
of death (Mexico and Italy with 73% and 51%, respect-
ively) (Table 2). Nursing homes were the predominant
sites of death in New Zealand (71%), Belgium (52%), and
USA (50%). Dying in an acute care hospital varied from
17% in USA to 75% in South Korea. In New Zealand, no
people living with Parkinson’s disease died in a hospice;
in the USA this was 4.0% (data not shown in Table 2).
Hospital death by patient and ecological characteristics
Men significantly more often than women died in
hospital in Belgium, France, Italy, USA and Canada
(Table 3). Younger patients more often died in a hospital
in Belgium, France, Italy, USA, Canada, and South
Korea. Significant differences according to educational
attainment were only found in Mexico, with those with
a higher education more often dying in a hospital.
Married persons more often than non-married persons
died in a hospital in Canada and France. In Italy and the
USA, hospital deaths were significantly more likely in
regions with a higher provision of hospital beds.Independent factors associated with hospital death
The multivariable binary regression analysis for each
country showed that the odds of male patients dying in
hospital were higher in Belgium, France, Italy, USA and
Canada (Table 4). Being younger than 80 years was asso-
ciated with higher odds of hospital death in Belgium,
France, Italy, USA and Mexico; but with lower odds of
dying in hospital in South Korea (odds ratio (OR) = 0.5,
95% confidence interval (CI) = 0.3-0.7). In Mexico, hav-
ing a higher education degree increased the odds of
dying in a hospital (OR = 1.8, 95% CI = 1.3-2.5). In
France, Hungary, USA and Canada, married patients
had a higher chance of dying in hospital. The Italian
people dying from Parkinson’s disease who lived in an
urban environment had a higher chance of dying in a
hospital (OR = 1.4, 95% CI = 1.2-1.6). Living in an area
with a higher provision of hospital beds increased the
odds of dying in hospital in Italy (OR = 5.3, 95%CI = 4.0-
7.1) and in the USA (OR = 1.1, 95% CI = 1.1-1.2), while
living in an area with a higher provision of LTC-beds
increased the odds of dying in hospital in France
(OR = 1.01, 95% CI = 1.002-1.014).
Discussion
The results of our study show that a substantial propor-
tion of persons living with Parkinson's disease died in
hospital in eleven European and non-European coun-
tries. However, cross-national variation in place of death
is striking.
To our knowledge this is the first cross-national study
to investigate place of death and associated factors
in people dying from Parkinson’s disease comparing
European and non-European countries. The death cer-
tificate data that we used were collected with established
and stable collection procedures resulting in reliable
data, comparable across nations. Death certificate data
comprise all deaths and not just a sample, giving suffi-
cient power to model determinants of place of death
even in small sub-populations, such as people who died
from Parkinson’s disease [12]. Some limitations of this
study exist, however. Parkinson’s disease is possibly
under-recorded on death certificates, particularly as an
underlying cause of death [13]. This introduces bias in
the estimation of the total population of people dying
with Parkinson’s disease (ie some patients will be re-
corded as having another underlying cause of death) but
produces less of a problem for the particular purpose of
our paper to describe where deaths from Parkinson’s
disease take place in different countries. The advantage
of only including deaths with Parkinson’s disease as an
‘underlying cause of death’ (as opposed to also including
those with Parkinson’s disease as a comorbidity) is that a
more homogenous group of patients is selected (who
were more likely to be in an advanced stage) and that at
Table 1 Characteristics of people dying from Parkinson’s disease (N = 34,430)
Characteristics Belgium France Italy Spain (Andalusia) Hungary Czech Republic New Zealand USA Canada Mexico South Korea
N of deaths (proportion on all deaths in %): 837(0.8) 4,599(0.8) 4,034(0.7) 352(0.6) 241(0.2) 92(0.1) 202(0.7) 20,065(0.8) 1,381(0.8) 1,062(0.2) 1,565(0.6)
Demographic and social factors
Sex:
male 52.0 53.2 50.0 55.4 58.5 58.7 52.5 57.6 56.3 55.7 43.7
female 48.0 46.8 50.0 44.6 41.5 41.3 47.5 42.4 43.7 44.3 56.3
Age:
<65 years 1.4 1.5 1.6 2.0 2.5§ 9.8 4.0 2.4 2.2 8.3 7.7
65 to 79 years 36.9 27.0 30.8 35.2 58.1 41.3 31.2 30.0 30.3 40.2 58.1
80+ years 61.6 71.5 67.6 62.8 39.3 48.9 64.9 67.7 67.6 51.5 34.2
Educational attainment:
no formal or elementary 44.9* _ 80.6 54.6 67.2 37.1 _ 7.4 _ 78.4 67.6
lower secondary 23.8 _ 10.9 28.1 0.4 48.3 _ 8.9 _ 1.6 _
higher secondary 22.4 _ 5.2 13.6 18.1 10.1 43.2 7.5 23.1
higher 8.9 _ 3.3 3.8 14.2 4.5 _ 40.5 _ 12.5 9.3
Social support
Marital status:
unmarried 5.9 8.8 9.5 8.7 5.8 1.1 _ 4.9 6.3 11.2 1.9
married 48.5 46.4 45.7 47.7 51.5 54.3 _ 48.4 48.8 51.6 49.6
widowed 40.6 40.8 44.0 42.4 37.3 34.8 _ 40.0 40.0 35.5 46.3
divorced/ separated 5.0 3.9 0.9 1.2 5.4 9.8 _ 6.7 4.9 1.7 2.3
Residential factors
Urbanization level:
very strong/strong 57.6 32.8 42.8 55.4 35.7 _ _ _ 82.8† _ 17.8
average 25.3 32.2 19.5 39.5 37.3 _ _ _ _ _ 20.9
weak/rural 17.1 35.0 37.6 5.1 27.0 _ _ _ 16.7† _ 61.3
Health care system factors
Hospital beds/1000 inhabitants 5.2 6.9 3.4 2.7 7.1‡ 6.0‡ 3.1 2.7 3.0 0.3 8.3‡
LTC-beds/1000 inhabitants age 65+ 70.3 58.4 34.6 17.7 32.7‡ 28.9‡ 71.6 41.5 58.1 0.0 17.5‡
‘-‘ in cells represents that this information was not available in the country’s death certificate data. Percentages are valid column percentages. Abbreviation: LTC Long Term Care.
*For Belgium 41.2% of the cases had missing information for educational attainment. Percentages are valid percentages only.
†Within Canada the urbanization level was categorized as ‘urban’ and ‘rural’.
‡Data were provided for the country as a whole.
§For Hungary the age distribution was provided in different ranges: <60; 60–79; 80 + .
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Table 2 Place of death of people dying from Parkinson’s disease (N = 34,430)
Belgium France Italy Spain (Andalusia) Hungary Czech Republic New Zealand USA Canada Mexico South Korea
Places of death*
Hospital 26.9 39.7 31.3 38.1 60.2 39.1 18.8 17.3 42.4 24.1 74.7
Home 20.8 33.4 51.0 46.0 _ 16.3 5.9 23.8 5.9 73.0 20.6
LTC-setting 51.7 24.2 13.4 15.1 _ 43.5 71.3 49.7 47.6 _ 4.5
Other 0.6 2.7 4.2 0.9 39.8 1.1 4.0 5.2 4.1 2.9 0.2
‘-‘ in cells represents that this information was not available in the country’s death certificate data. Percentages are valid column percentages.
Abbreviation: LTC Long Term Care.
*USA and New Zealand were the only countries where the death certificate data provided detail on hospice as a place of death. In the USA 4.0% died in a
hospice; in New Zealand this was 0.0%.
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not clearly died from Parkinson’s disease related symp-
toms and problems. Another limitation of our data is
that some socio demographic variables known to affect
place of death are not available [10]. Furthermore, death
certificate data do not provide insight beyond patterns in
place of death such as ‘quality of dying’ [12]. Nor do
they provide direct insight into the preferences, choices,
and decision-making from patients, families, health pro-
fessionals, and policy planners that underlie the statis-
tical patterns. Ideally, the found patterns are, however, a
good start for complementary qualitative research aimed
at getting a better understanding of these statistical
patterns.
In most countries included in our study, a substantial
proportion of people suffering from Parkinson’s disease
died in hospital. In people living with Parkinson’s
disease, LTC provision is possibly a factor explaining
variation in place of death. On average, 30-40% of
Parkinson’s disease patients develop dementia in an ad-
vanced disease stage [14], and having dementia increases
the chance of Parkinson’s disease patients being admit-
ted to a LTC-facility [4]. The low proportion of hospital
deaths in Belgium and New Zealand may be explained
by the higher provision of beds in LTC-settings [15].
South Korea showed the highest percentage of hospital
deaths (74.7%) which may be explained by the limited
provided LTC-facilities and the Korean LTC social insur-
ance scheme only coming into operation in July 2008
[16]. In France and Canada, countries that also have a
relatively high number of LTC-beds, the proportion of
hospital deaths was still substantial (39.7% and 42.4%
respectively), which in France may be explained by the
provision of long-term care in hospitals to some extent
[17]. An established LTC-sector in these countries may
therefore not be sufficient to balance for the high
hospital death proportions observed. LTC-facilities need
to have sufficient skilled nursing capacity and a well-
integrated palliative care policy to prevent hospitalisa-
tions at the end of life [18]. The implementation of
advance care planning and advance directives in thepolicy of LTC-facilities may be another important factor.
Evidence from the USA [19] and Belgium [20] has previ-
ously shown that written advance directives are associ-
ated with less likelihood of terminal hospitalisations.
The large cross-national differences in the proportion
dying in hospitals also partly have to be understood in
the context of health care organizational choices which
have in some countries placed a substantial part of long
term care or chronic care within the acute hospital set-
ting rather than in separate residential houses or institu-
tions. In Belgium, hospital death in people dying from
cancer was shown to be substantially higher than in
people dying from Parkinson’s disease, with 61% of
deaths from cancer occurring in hospital in 2003 [21].
This may be a result of the higher hospitalization rate in
advanced cancer patients, who are more often hospital-
ized because of acute pain and symptoms. People living
with Parkinson’s disease however have a longer disease
and care-need progression trajectory and their specific
symptoms are more easily dealt with within a LTC
setting [2], also showing to be the place of death where
a majority of our study population in Belgium died.
However, not only the specificity of the disease but also
societal norms and practices regarding end-of-life care
in people with Parkinson disease influence patterns of
their place of death in people with Parkinson disease.
The results of our multivariable binary logistic regres-
sion analyses showed that there are demographic and
social (support) factors that can be associated with in-
creased odds of dying in hospital in certain countries.
Being married increased the odds of death in hospital in
France, Hungary and Canada. Possibly, primary health
care and palliative home care services in those countries
are insufficiently established to support the primary
family caregivers in caring for a person living with
Parkinson’s disease at the advanced stage of the disease,
resulting in unplanned terminal hospitalizations. Being
younger than 80 years was another factor for hospital
deaths in Belgium, France, Italy, USA and Mexico. Pos-
sibly, younger people are less quickly shifted or referred
to palliative and LTC-settings. This could result in these
Table 3 Proportions of Parkinson’s disease deaths occurring in hospital by patient and ecological characteristics
(N = 34,430)
Characteristics Belgium France Italy Spain
(Andalusia)
Hungary Czech
Republic
New
Zealand
USA Canada Mexico South
Korea
Demographic and social factors
Sex:
male 33.1*** 46.3*** 34.6*** 39.0 63.8 38.9 23.6 19.8*** 50.0*** 23.7 74.1
female 20.1 32.3 28.1 36.9 55.0 39.5 13.5 14.1 32.7 24.6 75.1
Age:
<65 years 50.0*** 49.3*** 36.7*** 42.9 66.7§ 44.4 25.0 29.7*** 60.0** 23.3 80.0**
65 to 79 years 36.2 47.6 35.9 39.5 60.0§ 36.8 22.2 19.8 46.9 28.2 71.7
80+ years 20.7 36.6 29.1 37.1 60.0 40.0 16.8 15.8 39.9 21.2 78.5
Educational attainment:
no formal or elementary 25.8 _ 30.7 35.8 55.1 30.3 _ 19.6 _ 21.5*** 73.2
lower secondary 35.9 _ 36.6 43.8 100.0 39.5 _ 16.9 _ 31.3 _
higher secondary 32.7 _ 31.7 41.9 64.3 44.4 _ 17.2 _ 24.0 77.8
higher 27.3 _ 28.2 33.3 69.7 75.0 _ 17.3 _ 38.4 79.7
Social support
Marital status:
unmarried 24.5 32.9*** 30.1 26.7 57.1 0.0 _ 20.3*** 37.2*** 21.1 65.5**
married 31.1 47.0 32.7 42.7 67.7 42.0 _ 19.4 50.3 23.1 70.7
widowed 22.7 33.3 29.9 34.2 52.2 40.6 _ 14.2 33.6 25.3 79.3
divorced/ separated 21.4 36.7 40.5 75.0 46.2 22.2 _ 19.2 46.3 29.4 75.0
Residential factors
Urbanization level:
very strong/ strong 29.3 39.2 35.3*** 37.4 67.4 _ _ _ 42.9† _ 73.7**
average 24.5 39.5 35.8 38.1 51.1 _ _ _ _ _ 82.6
weak/ rural 22.4 – 40.5 24.6 44.4 63.1 _ _ _ 39.0† _ 72.3
Health care system factors
Hospital beds/ 1000 inhabitants:
<= median 25 40 23*** 40 ‡ ‡ 19.6 16.7* 41 23 ‡
> median 29 40 39 35 ‡ ‡ 17.8 18.0 44 25 ‡
LTC-beds/ 1000 inhabitants
age 65+:
<= median 27 39 23*** 36 ‡ ‡ 24.8 17.3 41 _ ‡
> median 27 41 39 40 ‡ ‡ 11.8 17.4 47 _ ‡
‘-‘ in cells represents that this information was not available in the country’s death certificate data. Percentages are row percentages. Abbreviation: LTC Long Term Care.
*Significant differences between categories within variable at 0.05 level, tested with Fisher Exact Test.; **Significant at 0.01 level ; ***Significant at 0.001 level.
†In the Canadian death certificate data the urbanization level was categorized as ‘urban’ and ‘rural’.
‡Data on the region of residence within the country was not provided in the country’s death certificate data and hence the data on health care availability was
for the country as a whole.
§For Hungary the age distribution was provided in different ranges: <60; 60–79; 80 + .
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male was a factor for hospital deaths in Belgium, France,
Italy, USA and Canada. There could be many reasons
for this, such as female persons who live with Parkinson’s
disease being more realistic in relation to their prog-
nosis and life expectancy, and them being more com-
municative concerning their wishes for care and place
of death [22].Home deaths are another option. In Italy, Spain and
Mexico, the majority of people living with Parkinson’s
disease died at home (51.0%, 46.0% and 73.0% respect-
ively). The high home death proportions in Italy [23]
and Spain [24] may be explained by cultural expectations
that families take care of their elderly and sick family
members. The high percentage of home deaths in
Mexico might be explained by limited choice for other
Table 4 Associated factors with hospital death in people dying from Parkinson’s disease (N = 34,430)
Characteristics Belgium France Italy Spain
(Andalusia)
Hungary Czech Republic New Zealand USA Canada Mexico South Korea
OR (95% CI)
Demographic and social factors
Sex:
Male (Vs. Female) 2.3 (1.5-3.5) 1.5 (1.3-1.7) 1.4 (1.2-1.6) NS NS NS NS 1.4 (1.3-1.5) 1.7 (1.4-2.2) NS NS
Age
<80 years (Vs. 80+) 1.8 (1.2-2.7) 1.4 (1.2-1.6) 1.4 (1.2-1.7) NS NS NS NS 1.3 (1.2-1.4) NS 1.4 (1.1-1.9) 0.8 (0.6-0.98)
Education:
Higher Secondary or Higher
(Vs. lower than higher secondary.)
NS - NS NS NS NS - NS - 1.8 (1.3-2.5) 0.6 (0.5-0.8)
Social support
Marital status
Married (Vs. Not/No longer married) NS 1.4 (1.2-1.6) NS NS 2.0 (1.2-3.4) NS - 1.1 (1.02-1.2) 1.5 (1.3-1.9) NS 0.6 (0.5-0.8)
Residential factors
Urbanization level:
Very strong/Strong
(Vs. average/weak/rural)
NS NS 1.4 (1.2-1.6) NS NS - - - NS - NS
Health care system factors
Hospital beds/1000 inhabitants
(Continuous)
NS NS 5.3 (4.0-7.1) NS * * NS 1.1 (1.1-1.2) NS NS *
LTC-beds/1000 inhabitants
65+ (Continuous)
NS 1.01 (1.002-1.014) NS NS * * 0.96 (0.92-0.99) NS NS - *
Nagelkerke R2 0.17 0.05 0.07 0 0.04 0 0 0.02 0.05 0.03 0.03
‘-‘ in cells represents the variable that was not available for this country and hence not included into the multivariable model.
Abbreviations: OR Odds Ratios, CI Confidence Interval, NS Not statistically Significant, LTC Long Term Care.
*Data only available for the country as a whole and hence not entered into the multivariable model.
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limited affordability of other health care services [25].
Larger families may also be important for home deaths,
as family caregivers are critical to home deaths [23,24].
Lastly, there is evidence that the development and
provision of palliative care vary greatly by country and
region [26,27] and are highly likely to influence place of
death.
At the national level, the statistical patterns we found
regarding country differences in place of death for
Parkinson’s disease and factors affecting these statistical
patterns can be used as a good starting point for both
researchers and policy makers to strive for a better under-
standing of these differences and development of possible
strategies for improvement. Although our data are only
sufficient to generate hypotheses regarding place of death
patterns, it may be suggested in line with previous re-
search, that communication concerning end-of-life care
wishes and place of death preferences should be initiated
early in the disease trajectory especially because of people
living with Parkinson’s disease having a high risk of devel-
oping cognitive impairment with dementia [14]. Advance
care planning could be used as a tool in this communica-
tion process. At the institutional level, there should also be
attention to the development of palliative services in LTC-
settings as it is expected that a considerable number of
people living with Parkinson’s disease will be cared for in
these settings [4]. Efforts are also needed to prevent
inappropriate hospital transfers near death for example by
providing more training on palliative care and the disease
progression and prognosis of people living with Parkinson’s
disease to LTC staff [28], providing more guidelines for
palliative care, and increasing financial reimbursement for
onsite palliative care delivery.
Our findings also call for a better understanding of the
general population’s knowledge of Parkinson’s disease
and its implications.
Conclusions
This study found considerable variability in the propor-
tion of deaths from Parkinson’s disease occurring in
hospital across eleven countries. Males and younger
people who live with Parkinson’s disease appear to be at
higher risk for hospital death.
Unless place of death becomes a major focus for quality
end-of-life care, we can expect that persons with serious
progressive illnesses, such as those who suffer from
Parkinson's disease, will continue to need to rely on
hospitals for terminal care. We suggest that end-of-life care
strategies should take into account the cultural factors that
influence preferences for terminal care and place of death,
the organization and functioning of health care systems,
and the way health care services are provided in order to
prevent people with Parkinson’s disease dying in hospitals.Competing interests
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